Download MendeleyDiscovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11 beta-Hydroxysteroid Dehydrogenase Type 1 (11 beta-HSD-1).
Li, J., Kennedy, L.J., Walker, S.J., Wang, H., Li, J.J., Hong, Z., O'Connor, S.P., Ye, X.Y., Chen, S., Wu, S., Yoon, D.S., Nayeem, A., Camac, D.M., Ramamurthy, V., Morin, P.E., Sheriff, S., Wang, M., Harper, T.W., Golla, R., Seethala, R., Harrity, T., Ponticiello, R.P., Morgan, N.N., Taylor, J.R., Zebo, R., Maxwell, B., Moulin, F., Gordon, D.A., Robl, J.A.(2018) ACS Med Chem Lett 9: 1170-1174
- PubMed: 30613321
- DOI: https://doi.org/10.1021/acsmedchemlett.8b00307
- Primary Citation of Related Structures:
5QII, 5QIJ - PubMed Abstract:
BMS-823778 ( 2 ), a 1,2,4-triazolopyridinyl-methanol derived analog, was identified as a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) enzyme (IC 50 = 2.3 nM) with >10,000-fold selectivity over 11β-HSD-2. Compound 2 exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED 50 = 0.6 mg/kg) and in diet-induced obese (DIO) mice (ED 50 = 34 mg/kg). Compound 2 also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED 50 = 5.2 mg/kg). Oral bioavailability ranges from 44% to 100% in preclinical species. Its favorable development properties, pharmacokinetics, high adipose-to-plasma concentration ratio, and preclinical pharmacology profile have prompted the evaluation of 2 for the treatment of type 2 diabetes and metabolic syndrome in phase 2 clinical trials.
Organizational Affiliation:
Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States.
